Selective inhibitors of RAF kinases, such as vemurafenib, regorafenib [12], and dabrafenib [13], have recently been introduced into clinical practice, and BRAF inhibitors have proved to be highly effective for the treatment of BRAF-mutant melanoma. The gene discussed is BRAF; the disease is melanoma.